Magnus Axelson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2019;12(1):80

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma

George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
Article: ONCOTARGET. 2017;8(46):81501-81510

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2017;77(3):184-189

Circulating androgens and SHBG during the normal menstrual cycle in two ethnic populations

Rezaii T; Gustafsson TP; Axelson M; Zamani L; Ernberg M; Hirschberg AL; Carlstrom KAM
Article: ACTA ONCOLOGICA. 2016;55(2):140-148

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial

Ekman S; Harmenberg J; Frodin J-E; Bergstrom S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund A; Alvfors C; Stahl B; Bergqvist M
Article: MEDICAL ONCOLOGY. 2015;32(7):188

Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells

Stromberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Article: ONCOTARGET. 2014;5(22):11193-11208

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic

Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
Article: ONCOTARGET. 2014;5(18):8379-8392

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism

Waraky A; Akopyan K; Parrow V; Stroemberg T; Axelson M; Abrahmsen L; Lindqvist A; Larsson O; Aleem E
Article: ORGANIC PROCESS RESEARCH & DEVELOPMENT. 2014;18(5):643-645

Facile Production Scale Synthesis of (S)-Taniguchi Lactone: A Precious Building-Block

von Kieseritzky F; Wang Y; Axelson M
Article: CLINICAL ENDOCRINOLOGY. 2013;78(5):700-705

Cortisol metabolism after weight loss: associations with 11 β-HSD type 1 and markers of obesity in women

Rask E; Simonyte K; Lonn L; Axelson M
Article: CLINICAL CANCER RESEARCH. 2012;18(8):2230-2239

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Osterborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2012;40(4):1251-1258

Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications

Feng X; Aleem E; Lin Y; Axelson M; Larsson O; Stromberg T
Article: PLOS ONE. 2011;6(3):e14757

Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)

Hashemi J; Worrall C; Vasilcanu D; Fryknas M; Sulaiman L; Karimi M; Weng W-H; Lui W-O; Rudduck C; Axelson M; Jernberg-Wiklund H; Girnita L; Larsson O; Larsson C
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2011;879(5-6):326-334

Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry

Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Beck O
Article: AMERICAN JOURNAL OF CANCER RESEARCH. 2011;1(3):356-361

Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation

Doghman M; Axelson M; Lalli E
Article: FERTILITY AND STERILITY. 2010;93(8):2621-2626

Selective insulin-like growth factor-I antagonist inhibits mouse embryo development in a dose-dependent manner

Inzunza J; Danielsson O; Lalitkumar PG; Larsson O; Axelson M; Tohonen V; Danielsson KG; Stavreus-Evers A
Article: NEURO-ONCOLOGY. 2010;12(1):19-27

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma

Yin S; Girnita A; Stromberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nister M; Larsson O; Ekstrom TJ; Girnita L
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(8):1458-1467

Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells (IGF1R^-/-) susceptible to oncogenic transformation

Natalishvili N; Axelson M; Girnita L; Larsson O; Vasilcanu D
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:42-49

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.

Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:35-41

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:26-34

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2620-2626

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2337-2342

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2008;368(3):793-800

Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth

Toernkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Article: FEBS JOURNAL. 2008;275(8):1778-1789

CYP7B1-mediated metabolism of dehydroepiandrosterone and 5α-androstane-3β,17β-diol -: potential role(s) for estrogen signaling

Pettersson H; Holmberg L; Axelson M; Norlin M
Article: ONCOGENE. 2008;27(11):1629-1638

Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1

Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Article: MOLECULAR PHARMACOLOGY. 2008;73(3):930-939

Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin

Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(8):1857-1861

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival

Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K
Article: JOURNAL OF VASCULAR SURGERY. 2007;46(1):108-115

The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling

Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
Article: JOURNAL OF LIPID RESEARCH. 2007;48(4):944-951

Novel route for elimination of brain oxysterols across the blood-brain barrier:: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid

Meaney S; Heverin M; Panzenboeck U; Ekstrom L; Axelsson M; Andersson U; Diczfalusy U; Pikuleva I; Wahren J; Sattler W; Bjorkhem I
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2007;320(2):695-705

Role of pituitary hormones on 17α-ethinylestradiol-induced cholestasis in rat

Henriquez-Hernandez LA; Flores-Morales A; Santana-Farre R; Axelson M; Nilsson P; Norstedt G; Fernandez-Perez L
Article: ENDOCRINOLOGY. 2007;148(1):128-139

Insulin-like growth factor-I is an important antiapoptotic factor for rat Leydig cells during postnatal development

Colon E; Zaman F; Axelson M; Larsson O; Carlsson-Skwirut C; Svechnikov KV; Soder O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;347(4):1059-1066

IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-)

Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
Article: CLINICAL CANCER RESEARCH. 2006;12(15):4506-4514

Hypoxia-inducible factor-1α- and hypoxia-inducible factor-2α are expressed in Kaposi sarcoma and modulated by insulin-like growth factor-I

Catrina S-B; Botusan IR; Rantanen A; Catrina AI; Pyakurel P; Savu O; Axelson M; Biberfeld P; Poellinger L; Brismar K
Article: ONCOGENE. 2006;25(22):3186-3195

The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection

Vasilcanu D; Weng W-H; Girnita A; Lui W-O; Vasilcanu R; Axelson M; Larsson O; Larsson C; Girnita L
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1383-1391

The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells

Girnita A; All-Ericsson C; Economou MA; Åström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: BLOOD. 2006;107(2):655-660

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

Menu E; Jernberg-Wiklund H; Stromberg T; De Raeve H; Girnita L; Larsson O; Axelson M; Asosingh K; Nilsson K; Van Camp B; Vanderkerken K
Article: BLOOD. 2006;107(2):669-678

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells

Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: BLOOD PRESSURE. 2006;15(3):169-172

The liquorice effect on the RAAS differs between the genders

Sigurjonsdottir HA; Axelson M; Johannsson G; Manhem K; Nystrom E; Wallerstedt S
Article: HORMONE RESEARCH IN PAEDIATRICS. 2006;65(2):106-110

Liquorice in moderate doses does not affect sex steroid hormones of biological importance although the effect differs between the genders

Sigurjonsdottir HA; Axelson M; Johannsson G; Manhem K; Nyström E; Wallerstedt S
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2006;154(1):69-74

GH effect on enzyme activity of 11βHSD in abdominal obesity is dependent on treatment duration

Sigurjónsdóttir HA; Koranyi J; Axelson M; Bengtsson B; Johannsson G
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(31):28324-28331

A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1

Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4674-4680

Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells:: A novel therapeutic approach

Ulfarsson E; Karström A; Yin SC; Girnita A; Vasilcanu D; Thoren M; Kratz G; Hillman J; Axelson M; Larsson O; Girnita L
Article: BRITISH JOURNAL OF CANCER. 2005;92(8):1467-1474

Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival

Catrina SB; Lewitt M; Massambu C; Dricu A; Grünler J; Axelson M; Biberfeld P; Brismar K
Article: ONCOGENE. 2004;23(47):7854-7862

The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway

Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Article: BRITISH JOURNAL OF NUTRITION. 2004;91(6):959-969

Lipoprotein metabolism in patients with anorexia nervosa:: a case-control study investigating the mechanisms leading to hypercholesterolaemia

Weinbrenner T; Züger M; Jacoby GE; Herpertz S; Liedtke R; Sudhop T; Gouni-Berthold I; Axelson M; Berthold HK
Article: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2004;42(6):307-313

Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men

Lütjohann D; Hahn C; Prange W; Sudhop T; Axelson M; Sauerbruch T; von Bergmann K; Reichel C
Article: CANCER RESEARCH. 2004;64(1):236-242

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth

Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
Article: HEPATOLOGY. 2003;38(4):930-938

Feedback regulation of bile acid synthesis in primary human hepatocytes:: Evidence that CDCA is the strongest inhibitor

Ellis E; Axelson M; Abrahamsson A; Eggertsen G; Thörne A; Nowak G; Ericzon BG; Björkhem I; Einarsson C
Article: STEROIDS. 2003;68(7-8):595-601

On the origin of the cholestenoic acids in human circulation

Meaney S; Babiker A; Lütjohann D; Diczfalusy U; Axelson M; Bjrökhem I
Article: JOURNAL OF HUMAN HYPERTENSION. 2003;17(2):125-131

Subjects with essential hypertension are more sensitive to the inhibition of 11 β-HSD by liquorice

Sigurjonsdottir HA; Manhem K; Axelson M; Wallerstedt S
Article: CANCER LETTERS. 2001;170(2):169-175

Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis

Tatidis L; Vitols S; Gruber A; Paul C; Axelson M
Article: HEPATOLOGY. 2001;33(5):1189-1193

Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects

Einarsson C; Hillebrant CG; Axelson M
Article: WORLD JOURNAL OF GASTROENTEROLOGY. 2000;6(4):522-525

Bile acid formation in primary human hepatocytes

Einarsson C; Ellis E; Abrahamsson A; Ericzon BG; Björkhem I; Axelson M
Article: HEPATOLOGY. 2000;31(6):1305-1312

Bile acid synthesis in cultured human hepatocytes:: Support for an alternative biosynthetic pathway to cholic acid

Axelson M; Ellis E; Mörk B; Garmark K; Abrahamsson A; Björkhem I; Ericzon BG; Einarsson C
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2000;29(2):89-94

Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon®) in patients with rheumatoid arthritis

Carlström K; Hedin PJ; Jönsson L; Lerndal T; Lien J; Weitoft T; Axelson M
Article: JOURNAL OF INTERNAL MEDICINE. 1999;246(4):399-407

Deoxycholic acid treatment in patients with cholesterol gallstones:: failure to detect a suppression of cholesterol 7α-hydroxylase activity

Hillebrant CG; Nyberg B; Angelin B; Axelson M; Björkhem I; Rudling M; Einarsson C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1999;29(5):404-412

Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis:: contrasting findings in patients with and without prior up-regulation of the latter pathway

Naoumova RP; O'Neill FH; Dunn S; Neuwirth CKY; Taylor GW; Axelson M; Thompson GR
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 1999;84(4):1210-1213

Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11β-hydroxysteroid dehydrogenase reductase activity

Nordenström A; Marcus C; Axelson M; Wedell A; Ritzén EM
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 1998;1394(2-3):153-157

The level of 7-dehydrocholesterol in plasma reflects the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the human liver

Axelson M; Angelin B; Hillebrant CG; Reihner E; Einarsson C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1998;28(4):324-328

Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients

Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
Article: HEPATOLOGY. 1997;26(6):1573-1579

Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy

Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjovall J
Article: JOURNAL OF HEPATOLOGY. 1997;27(1):150-155

Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects

Muhrbeck O; Wang FH; Bjorkhem I; Axelson M; Einarsson K
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1997;27(5):387-391

The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: Prolongation of the nucleation time

Gustafsson U; Wang FH; Axelson M; Kallner A; Sahlin S; Einarsson K
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(22):12724-12736

27-Hydroxylated low density lipoprotein (LDL) cholesterol can be converted to 7 alpha,27-dihydroxy-4-cholesten-3-one (cytosterone) before suppressing cholesterol production in normal human fibroblasts - Evidence that an altered metabolism of LDL cholesterol can underlie a defective feedback control in malignant cells

Axelson M; Larsson O
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1995;270(25):15102-15110

LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL IS CONVERTED TO 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS - EVIDENCE THAT 27-HYDROXYCHOLESTEROL CAN BE AN IMPORTANT INTRACELLULAR MEDIATOR BETWEEN LDL AND THE SUPPRESSION OF CHOLESTEROL PRODUCTION

AXELSON M; LARSSON O
Article: JOURNAL OF LIPID RESEARCH. 1995;36(2):290-298

STRUCTURAL SPECIFICITY IN THE SUPPRESSION OF HMG-COA REDUCTASE IN HUMAN FIBROBLASTS BY INTERMEDIATES IN BILE-ACID BIOSYNTHESIS

AXELSON M; LARSSON O; ZHANG J; SHODA J; SJOVALL J
Visa fler

Alla övriga publikationer

Corrigendum: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2012;889:148

Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry (vol 879, pg 326, 2011)

Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Ekman S; Bergqvist M; Beck O
Meeting abstract: JOURNAL OF VASCULAR SURGERY. 2010;51:72S-73S

A Specific Inhibitor of IGF-1 Receptor - Picropodophyllin Can Suppress Atheroma Progression and Has a Stabilizing Effect on Atherosclerotic Lesions in ApoE Deficient Mice

Razuvaev A; Larsson O; Axelson M; Hedin U; Roy J
Letter: CANCER RESEARCH. 2007;67(6):2899-2900

Cyclolignans as inhibitors of the insulin-like growth factor-I receptor

Larsson O; Axelson M
Meeting abstract: BLOOD. 2004;104(11):184A-185A

Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.

Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2004;50(3):P117

Possible use of flavonoids as cell growth inhibitors in malignant melanoma

Girnita A; Girnita L; Axelson M; Larsson O
Letter: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2001;86(3):1426-1427

Defective 11β-HSD reductase activity in a patient with congenital adrenal hyperplasia

Nordenstrom A; Marcus C; Axelson M; Wedell A; Ritzén M
Meeting abstract: GASTROENTEROLOGY. 2000;118(4):A450

The effects of treatment with chenodeoxycholic acid and deoxycholic acid on cholesterol and bile acid synthesis in healthy subjects.

Hillebrant CG; Axelsson M; Einarsson C

Anställningar

Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, Professor i klinisk kemi (adj./aff.) sedan 2000-05-01., Karolinska Institutet, 1980

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI